Research programme: dihydrocostatolide - National Cancer Institute/Sarawak MediChem

Drug Profile

Research programme: dihydrocostatolide - National Cancer Institute/Sarawak MediChem

Alternative Names: (-)-Dihydrocalanolide B; 7,8-Dihydrocostatolide; Dihydrocodstatolide; NSC 661123

Latest Information Update: 02 Mar 2009

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Class Antivirals; Coumarins; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 01 Oct 1999 A study has been added to the antimicrobial activities section
  • 30 Jan 1996 Preclinical development for HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top